Literature DB >> 22886699

Hexa-D-arginine treatment increases 7B2•PC2 activity in hyp-mouse osteoblasts and rescues the HYP phenotype.

Baozhi Yuan1, Jian Q Feng, Stephen Bowman, Ying Liu, Robert D Blank, Iris Lindberg, Marc K Drezner.   

Abstract

Inactivating mutations of the "phosphate regulating gene with homologies to endopeptidases on the X chromosome" (PHEX/Phex) underlie disease in patients with X-linked hypophosphatemia (XLH) and the hyp-mouse, a murine homologue of the human disorder. Although increased serum fibroblast growth factor 23 (FGF-23) underlies the HYP phenotype, the mechanism(s) by which PHEX mutations inhibit FGF-23 degradation and/or enhance production remains unknown. Here we show that treatment of wild-type mice with the proprotein convertase (PC) inhibitor, decanoyl-Arg-Val-Lys-Arg-chloromethyl ketone (Dec), increases serum FGF-23 and produces the HYP phenotype. Because PC2 is uniquely colocalized with PHEX in osteoblasts/bone, we examined if PC2 regulates PHEX-dependent FGF-23 cleavage and production. Transfection of murine osteoblasts with PC2 and its chaperone protein 7B2 cleaved FGF-23, whereas Signe1 (7B2) RNA interference (RNAi) transfection, which limited 7B2 protein production, decreased FGF-23 degradation and increased Fgf-23 mRNA and protein. The mechanism by which decreased 7B2PC2 activity influences Fgf-23 mRNA was linked to reduced conversion of the precursor to bone morphogenetic protein 1 (proBMP1) to active BMP1, which resulted in limited cleavage of dentin matrix acidic phosphoprotein 1 (DMP1), and consequent increased Fgf-23 mRNA. The significance of decreased 7B2PC2 activity in XLH was confirmed by studies of hyp-mouse bone, which revealed significantly decreased Sgne1 (7B2) mRNA and 7B2 protein, and limited cleavage of proPC2 to active PC2. The expected downstream effects of these changes included decreased FGF-23 cleavage and increased FGF-23 synthesis, secondary to decreased BMP1-mediated degradation of DMP1. Subsequent Hexa-D-Arginine treatment of hyp-mice enhanced bone 7B2PC2 activity, normalized FGF-23 degradation and production, and rescued the HYP phenotype. These data suggest that decreased PHEX-dependent 7B2PC2 activity is central to the pathogenesis of XLH.
Copyright © 2013 American Society for Bone and Mineral Research.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 22886699      PMCID: PMC3523095          DOI: 10.1002/jbmr.1738

Source DB:  PubMed          Journal:  J Bone Miner Res        ISSN: 0884-0431            Impact factor:   6.741


  68 in total

1.  Processing and sorting of the prohormone convertase 2 propeptide.

Authors:  L Muller; A Cameron; Y Fortenberry; E V Apletalina; I Lindberg
Journal:  J Biol Chem       Date:  2000-12-15       Impact factor: 5.157

2.  Overexpression of Phex in osteoblasts fails to rescue the Hyp mouse phenotype.

Authors:  Shiguang Liu; Rong Guo; Qisheng Tu; L Darryl Quarles
Journal:  J Biol Chem       Date:  2001-11-16       Impact factor: 5.157

3.  7B2 is a neuroendocrine chaperone that transiently interacts with prohormone convertase PC2 in the secretory pathway.

Authors:  J A Braks; G J Martens
Journal:  Cell       Date:  1994-07-29       Impact factor: 41.582

4.  The efficacy of vitamin D2 and oral phosphorus therapy in X-linked hypophosphatemic rickets and osteomalacia.

Authors:  K W Lyles; J M Harrelson; M K Drezner
Journal:  J Clin Endocrinol Metab       Date:  1982-02       Impact factor: 5.958

5.  Autosomal-dominant hypophosphatemic rickets (ADHR) mutations stabilize FGF-23.

Authors:  K E White; G Carn; B Lorenz-Depiereux; A Benet-Pages; T M Strom; M J Econs
Journal:  Kidney Int       Date:  2001-12       Impact factor: 10.612

6.  Polyarginines are potent furin inhibitors.

Authors:  A Cameron; J Appel; R A Houghten; I Lindberg
Journal:  J Biol Chem       Date:  2000-11-24       Impact factor: 5.157

7.  Cloning and characterization of FGF23 as a causative factor of tumor-induced osteomalacia.

Authors:  T Shimada; S Mizutani; T Muto; T Yoneya; R Hino; S Takeda; Y Takeuchi; T Fujita; S Fukumoto; T Yamashita
Journal:  Proc Natl Acad Sci U S A       Date:  2001-05-08       Impact factor: 11.205

8.  Evaluation of a role for 1,25-dihydroxyvitamin D3 in the pathogenesis and treatment of X-linked hypophosphatemic rickets and osteomalacia.

Authors:  M K Drezner; K W Lyles; M R Haussler; J M Harrelson
Journal:  J Clin Invest       Date:  1980-11       Impact factor: 14.808

9.  Abnormal regulation of renal 25-hydroxyvitamin D-1 alpha-hydroxylase activity in the X-linked hypophosphatemic mouse.

Authors:  B Lobaugh; M K Drezner
Journal:  J Clin Invest       Date:  1983-02       Impact factor: 14.808

10.  7B2 is a specific intracellular binding protein of the prohormone convertase PC2.

Authors:  S Benjannet; D Savaria; M Chrétien; N G Seidah
Journal:  J Neurochem       Date:  1995-05       Impact factor: 5.372

View more
  26 in total

Review 1.  The rachitic tooth.

Authors:  Brian L Foster; Francisco H Nociti; Martha J Somerman
Journal:  Endocr Rev       Date:  2013-12-04       Impact factor: 19.871

Review 2.  Fibroblast growth factor 23 in acute kidney injury.

Authors:  Marta Christov
Journal:  Curr Opin Nephrol Hypertens       Date:  2014-07       Impact factor: 2.894

Review 3.  Hypophosphatemic rickets: revealing novel control points for phosphate homeostasis.

Authors:  Kenneth E White; Julia M Hum; Michael J Econs
Journal:  Curr Osteoporos Rep       Date:  2014-09       Impact factor: 5.096

4.  Sclerostin antibody (Scl-Ab) improves osteomalacia phenotype in dentin matrix protein 1(Dmp1) knockout mice with little impact on serum levels of phosphorus and FGF23.

Authors:  Yinshi Ren; Xianglong Han; Yan Jing; Baozhi Yuan; Huazhu Ke; Min Liu; Jian Q Feng
Journal:  Matrix Biol       Date:  2015-12-22       Impact factor: 11.583

5.  Iron and fibroblast growth factor 23 in X-linked hypophosphatemia.

Authors:  Erik A Imel; Amie K Gray; Leah R Padgett; Michael J Econs
Journal:  Bone       Date:  2013-12-08       Impact factor: 4.398

Review 6.  The Causes of Hypo- and Hyperphosphatemia in Humans.

Authors:  Eugénie Koumakis; Catherine Cormier; Christian Roux; Karine Briot
Journal:  Calcif Tissue Int       Date:  2020-04-13       Impact factor: 4.333

Review 7.  Fibrous dysplasia and fibroblast growth factor-23 regulation.

Authors:  Alison M Boyce; Nisan Bhattacharyya; Michael T Collins
Journal:  Curr Osteoporos Rep       Date:  2013-06       Impact factor: 5.096

8.  Family with sequence similarity member 20C is the primary but not the only kinase for the small-integrin-binding ligand N-linked glycoproteins in bone.

Authors:  Xiudong Yang; Wenjuan Yan; Ye Tian; Pan Ma; Lynne A Opperman; Xiaofang Wang
Journal:  FASEB J       Date:  2015-08-31       Impact factor: 5.191

9.  Posttranslational processing of FGF23 in osteocytes during the osteoblast to osteocyte transition.

Authors:  Hiroyuki Yamamoto; Bruno Ramos-Molina; Adam N Lick; Matthew Prideaux; Valeria Albornoz; Lynda Bonewald; Iris Lindberg
Journal:  Bone       Date:  2015-12-31       Impact factor: 4.398

Review 10.  Osteocyte regulation of phosphate homeostasis and bone mineralization underlies the pathophysiology of the heritable disorders of rickets and osteomalacia.

Authors:  Jian Q Feng; Erica L Clinkenbeard; Baozhi Yuan; Kenneth E White; Marc K Drezner
Journal:  Bone       Date:  2013-02-09       Impact factor: 4.398

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.